These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 15762187)

  • 1. Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Eur J Endocrinol; 2005 Jan; 152(1):53-60. PubMed ID: 15762187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadal status is an important determinant of bone density in acromegaly.
    Lesse GP; Fraser WD; Farquharson R; Hipkin L; Vora JP
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):59-65. PubMed ID: 9509069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density of the axial skeleton in acromegaly.
    Ho PJ; Fig LM; Barkan AL; Shapiro B
    J Nucl Med; 1992 Sep; 33(9):1608-12. PubMed ID: 1517833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function.
    Bolanowski M; Daroszewski J; Medraś M; Zadrozna-Sliwka B
    J Bone Miner Metab; 2006; 24(1):72-8. PubMed ID: 16369902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study.
    Drake WM; Rodríguez-Arnao J; Weaver JU; James IT; Coyte D; Spector TD; Besser GM; Monson JP
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):525-32. PubMed ID: 11318789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly.
    Madeira M; Neto LV; de Lima GA; Moreira RO; de Mendonça LM; Gadelha MR; Farias ML
    Osteoporos Int; 2010 Dec; 21(12):2019-25. PubMed ID: 20306022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone metabolism and body composition in Japanese patients with active acromegaly.
    Kaji H; Sugimoto T; Nakaoka D; Okimura Y; Kaji H; Abe H; Chihara K
    Clin Endocrinol (Oxf); 2001 Aug; 55(2):175-81. PubMed ID: 11531923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender.
    Zgliczynski W; Kochman M; Misiorowski W; Zdunowski P
    Neuro Endocrinol Lett; 2007 Oct; 28(5):621-8. PubMed ID: 17984937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
    Janssen YJ; Hamdy NA; Frölich M; Roelfsema F
    J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status.
    Scillitani A; Battista C; Chiodini I; Carnevale V; Fusilli S; Ciccarelli E; Terzolo M; Oppizzi G; Arosio M; Gasperi M; Arnaldi G; Colao A; Baldelli R; Ghiggi MR; Gaia D; Di Somma C; Trischitta V; Liuzzi A
    Clin Endocrinol (Oxf); 2003 Jun; 58(6):725-31. PubMed ID: 12780749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients.
    Ueland T; Fougner SL; Godang K; Schreiner T; Bollerslev J
    Eur J Endocrinol; 2006 Nov; 155(5):709-15. PubMed ID: 17062887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential presentation of cortical and trabecular peripheral bone mineral density in acromegaly.
    Jockenhövel F; Rohrbach S; Deggerich S; Reinwein D; Reiners C
    Eur J Med Res; 1996 May; 1(8):377-82. PubMed ID: 9360937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism.
    Colao A; Di Somma C; Pivonello R; Loche S; Aimaretti G; Cerbone G; Faggiano A; Corneli G; Ghigo E; Lombardi G
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1919-24. PubMed ID: 10372687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a growth hormone receptor antagonist on bone markers in acromegaly.
    Fairfield WP; Sesmilo G; Katznelson L; Pulaski K; Freda PU; Stavrou S; Kleinberg D; Klibanski A
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):385-90. PubMed ID: 12201832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone and sex steroid effects on bone metabolism and bone mineral density in healthy aged women and men.
    Christmas C; O'Connor KG; Harman SM; Tobin JD; Münzer T; Bellantoni MF; Clair CS; Pabst KM; Sorkin JD; Blackman MR
    J Gerontol A Biol Sci Med Sci; 2002 Jan; 57(1):M12-8. PubMed ID: 11773207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients.
    Scillitani A; Chiodini I; Carnevale V; Giannatempo GM; Frusciante V; Villella M; Pileri M; Guglielmi G; Di Giorgio A; Modoni S; Fusilli S; Di Cerbo A; Liuzzi A
    J Bone Miner Res; 1997 Oct; 12(10):1729-36. PubMed ID: 9333135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine.
    Kayath MJ; Vieira JG
    Osteoporos Int; 1997; 7(3):226-30. PubMed ID: 9205635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.